Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Brooklyn Larimore, Mark Gilbert, PhD, and William M. Lydiatt, MD, MBA
Portraits of clinicians quickly became emblematic of what the COVID-19 pandemic has demanded of all of us, especially caregivers who witnessed deaths likely unprecedented in number during their careers.
AMA J Ethics. 2022;24(7):E667-675. doi:
10.1001/amajethics.2022.667.
This first-person narrative illuminates how the author—a nurse, artist, and dancer—uses the arts and movement to help patients and clinicians process personal loss individually and collectively in the hospital setting.
AMA J Ethics. 2022;24(7):E681-684. doi:
10.1001/amajethics.2022.681.